Business
NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke Universi
About this update from Neonc Technologies Holdings, Inc.
[{"type":"image","alt":"NeOnc Technologies Holdings, Inc.","displaySize":"","headline":null,"caption":"NeOnc Technologies Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/b347a68adadea2a3bd45b7a77e70bf38"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/31EVIWakRB17XYBfbTJVvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b347a68adadea2a3bd45b7a77e70bf38","width":300,"height":93}},"lazy":false},{"type":"text","content":"CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is the author of more than 500 peer reviewed articles, reviews, and book chapters and has presented extensively at both international and national meetings.","length":663,"tagName":"p"},{"type":"text","content":"“We are incredibly honored to welcome Dr. Henry Friedman, a true luminary in the field of neuro-oncology, to our scientific advisory board,” said Amir F. Heshmatpour, Executive Chairman and President of NeOnc Technologies. “His profound experience in developing novel therapies for CNS cancers and his distinguished career at Duke’s Preston Robert Tisch Brain Tumor Center will be invaluable as we advance our pipeline, including our lead candidates NEO100™ and NEO212™.","length":470,"tagName":"p"},{"type":"text","content":"Mr. Heshmatpour added, “As NeOnc prepares to publish upcoming data from our NEO100 and NEO212 clinical programs, we look forward to our key opinion leaders carefully reviewing and validating these results. We believe their independent expertise will not only strengthen the confidence of our stakeholders but will also mark a turning point—one of destiny—for patients and families battling glioblastoma and other brain cancers. Together, with the guidance of leaders like Dr. Friedman, we are committed to changing the future for those who need it most.”","length":554,...